|
| Status |
Public on Feb 10, 2019 |
| Title |
Catalytic subunits switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells [ChIP-seq] |
| Organism |
Homo sapiens |
| Experiment type |
Genome binding/occupancy profiling by high throughput sequencing
|
| Summary |
The SWI/SNF chromatin remodeling complex is altered in ~20% of human cancers. ARID1A, a component of the SWI/SNF chromatin-remodeling complex, is the most frequently mutated epigenetic regulator in human cancers. Inactivation of the SWI/SNF complex is synthetically lethal with inhibition of EZH2 activity. EZH2 inhibitors are entering clinical trials for specific tumor types with SWI/SNF mutations. However, mechanisms of de novo or acquired resistance to EZH2 inhibitors in cancers with inactivating SWI/SNF mutations are unknown. Here we show that the switch of the SWI/SNF catalytic subunits from SMARCA4 to SMARCA2 drives resistance to EZH2 inhibitors in ARID1A-mutated ovarian cancer cells.
|
| |
|
| Overall design |
Parental TOV21G cell line and and resistant to EZH2 inhibitor GSK126 treatment clones were assayed by RNA-seq and BRG1 CHIP-seq
|
| |
|
| Contributor(s) |
Zhang R, Wu S |
| Citation(s) |
30297712 |
| |
| Submission date |
Feb 10, 2018 |
| Last update date |
Jan 06, 2020 |
| Contact name |
Priyankara J Wickramasinghe |
| E-mail(s) |
[email protected]
|
| Phone |
2154956837
|
| Organization name |
The Wistar Institute
|
| Department |
Bioinformatics
|
| Lab |
Genomics
|
| Street address |
3601 Spruce Street
|
| City |
Philadelphia |
| State/province |
PA |
| ZIP/Postal code |
19104 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL18573 |
Illumina NextSeq 500 (Homo sapiens) |
|
| Samples (2) |
| GSM2991371 |
BRG1 binding in parental TOV21G cell line |
| GSM2991372 |
BRG1 binding in resistant clone 3 of TOV21G cell line |
|
| This SubSeries is part of SuperSeries: |
| GSE110450 |
Catalytic subunits switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells |
|
| Relations |
| BioProject |
PRJNA433733 |
| SRA |
SRP132631 |
